Navigating the Storm: Understanding and Managing Depression During Menopause in Women
Abstract
Depression has a prevalence of about 280-300 million individuals globally and is more prevalent in women than in men. Hormonal changes, vasomotor changes and psychosocial factors are linked with the high risk of depression during menopausal transition. Oestrogen also acts upon serotonergic, dopaminergic and noradrenergic processes, which are involved in mood regulation, indicating a biological association between menopause and depression. Aim of this review was to examine the mechanisms underlying menopause-related depression and summarise existing management strategies A literature review was based on published articles and clinical guidelines was conducted to investigate the relationship between menopause, hormonal changes and depression and the assessment of treatment options. Studies indicate a close relationship between menopausal transition and symptoms of depression. Factors that increase the risk of experiencing vasomotor symptoms, a negative attitude to menopause, surgical menopause and a previous history of depression are some of the risk factors. Several diagnostic tools are common, such as the Beck Depression Inventory and the Hamilton depression rating scale. There is evidence of the usefulness of menopausal hormone therapy (MHT) in the treatment of both menopausal and depressive symptoms. Adjunctive measures, such as antidepressants, phytoestrogens, B vitamins, vitamin D, magnesium and polyunsaturated fatty acids, have also been shown to have other advantages in the treatment of mood disturbances and psychosocial discomfort. Menopause-related depression is a growing issue in the population that has causes with multifactorial predictors. A combined management approach of MHT, nutritional supplements and psychosocial interventions is needed to enhance the quality of life and the psychological well-being of perimenopausal and postmenopausal women.
References
Meeta M, Digumarti L, Agarwal N, Vaze N, Shah R, Malik S. Clinical practice guidelines on menopause: an executive summary and recommendations: Indian Menopause Society 2019–2020. J Midlife Health. 2020 Apr–Jun;11(2):55-95. doi: 10.4103/jmh.JMH_137_20.
World Health Organization. Menopause [Internet]. 2022 [Cited: 20-Jun-2023]. Available from: https://www.who.int/news-room/fact.
Prasad JB, Tyagi NK, Verma P. Age at menopause in India: a systematic review. Diabetes Metab Syndr. 2021 Jan–Feb;15(1):373-7. doi: 10.1016/j.dsx.2021.01.013.
World Health Organization. Depressive disorder [Internet]. 2023 [Cited: 31-Mar-2023]. Available from: https://www.who.int/news-room/fact-sheets/detail/depression/?gclid=CjwKCAiA8NKtBhBtEiwAq5aX2I5zuzS5csP4aab-Na0aMrjOugk7sCVCsEc0ZLyZ0Cwk5Y5MME8BlhoCIGEQAvD_BwE.
Remes O, Mendes JF, Templeton P. Biological, psychological, and social determinants of depression: a review of recent literature. Brain Sci. 2021 Dec 10;11(12):1633. doi: 10.3390/brainsci11121633.
Peacock K, Carlson K, Ketvertis KM. Menopause. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2024 [Updated: 21-Dec-2023]. Available from: https://www.ncbi.nlm.nih.gov/books/NBK507826/.
Alblooshi S, Taylor M, Gill N. Does menopause elevate the risk for developing depression and anxiety? Results from a systematic review. Australas Psychiatry. 2023 Apr;31(2):165-73. doi: 10.1177/10398562231165439.
Kundakovic M, Rocks D. Sex hormone fluctuation and increased female risk for depression and anxiety disorders: from clinical evidence to molecular mechanisms. Front Neuroendocrinol. 2022 Jul;66:101010. doi: 10.1016/j.yfrne.2022.101010.
Cohen LS, Soares CN, Vitonis AF, Otto MW, Harlow BL. Risk for new onset of depression during the menopausal transition: the Harvard study of moods and cycles. Arch Gen Psychiatry. 2006 Apr;63(4):385-90. doi: 10.1001/archpsyc.63.4.385.
Yadav V, Jain A, Dabar D, Goel AD, Sood A, Joshi A, et al. A meta-analysis on the prevalence of depression in perimenopausal and postmenopausal women in India. Asian J Psychiatr. 2021 Mar;57:102581. doi: 10.1016/j.ajp.2021.102581.
Freeman EW, Sammel MD, Lin H, Nelson DB. Associations of hormones and menopausal status with depressed mood in women with no history of depression. Arch Gen Psychiatry. 2006 Apr;63(4):375-82. doi: 10.1001/archpsyc.63.4.375.
Almeida OP, Marsh K, Flicker L, Hickey M, Sim M, Ford A. Depressive symptoms in midlife: the role of reproductive stage. Menopause. 2016 Jun;23(6):669-75. doi: 10.1097/GME.0000000000000598.
Padda J, Khalid K, Hitawala G, Batra N, Pokhriyal S, Mohan A, et al. Depression and its effect on the menstrual cycle. Cureus. 2021 Jul 21;13(7):e16532. doi: 10.7759/cureus.16532.
Albert PR. Why is depression more prevalent in women? J Psychiatry Neurosci. 2015 Jul;40(4):219-21. doi: 10.1503/jpn.150205.
Shea AK, Sohel N, Gilsing A, Mayhew AJ, Griffith LE, Raina P. Depression, hormone therapy, and the menopausal transition among women aged 45 to 64 years using Canadian Longitudinal Study on Aging baseline data. Menopause. 2020 Jul;27(7):763-70. doi: 10.1097/GME.0000000000001540.
Campbell KE, Dennerstein L, Finch S, Szoeke CE. Impact of menopausal status on negative mood and depressive symptoms in a longitudinal sample spanning 20 years. Menopause. 2017 May;24(5):490-6. doi: 10.1097/GME.0000000000000805.
Georgakis MK, Thomopoulos TP, Diamantaras AA, Kalogirou EI, Skalkidou A, Daskalopoulou SS, et al. Association of age at menopause and duration of reproductive period with depression after menopause: a systematic review and meta-analysis. JAMA Psychiatry. 2016 Feb;73(2):139-49. doi: 10.1001/jamapsychiatry.2015.2653.
Bove R, Secor E, Chibnik LB, Barnes LL, Schneider JA, Bennett DA, De Jager PL. Age at surgical menopause influences cognitive decline and Alzheimer pathology in older women. Neurology. 2014 Jan 21;82(3):222-9. doi: 10.1212/WNL.0000000000000033.
Ahlawat P, Singh MM, Garg S, Mala YM. Prevalence of depression and its association with sociodemographic factors in postmenopausal women in an urban resettlement colony of Delhi. J Midlife Health. 2019 Jan–Mar;10(1):33-6. doi: 10.4103/jmh.JMH_66_18.
Wasnik VB, Acharya N, Mohammad S. Genitourinary syndrome of menopause: a narrative review focusing on its effects on the sexual health and quality of life of women. Cureus. 2023 Nov 2;15(11):e48143. doi: 10.7759/cureus.48143.
Muka T, Oliver Williams C, Colpani V, Kunutsor S, Chowdhury S, Chowdhury R, et al. Association of vasomotor and other menopausal symptoms with risk of cardiovascular disease: a systematic review and meta-analysis. PLoS One. 2016 Jun 17;11(6):e0157417. doi: 10.1371/journal.pone.0157417.
Stuenkel CA, Davis SR, Gompel A, Lumsden MA, Murad MH, Pinkerton JV, et al. Treatment of symptoms of the menopause: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2015 Nov;100(11):3975-4011. doi: 10.1210/jc.2015-2236.
Worsley R, Bell R, Kulkarni J, Davis SR. The association between vasomotor symptoms and depression during perimenopause: a systematic review. Maturitas. 2014 Feb;77(2):111-7. doi: 10.1016/j.maturitas.2013.11.007.
Herson M, Kulkarni J. Hormonal agents for the treatment of depression associated with the menopause. Drugs Aging. 2022 Aug;39(8):607-18. doi: 10.1007/s40266-022-00962-x.
Chu K, Shui J, Ma L, Huang Y, Wu F, Wei F, et al. Biopsychosocial risk factors of depression during menopause transition in southeast China. BMC Womens Health. 2022 Jul 5;22(1):273. doi: 10.1186/s12905-022-01710-4.
Fenton A. Weight, shape, and body composition changes at menopause. J Midlife Health. 2021 Jul–Sep;12(3):187-92. doi: 10.4103/jmh.jmh_123_21.
Baker FC, Lampio L, Saaresranta T, Polo Kantola P. Sleep and sleep disorders in the menopausal transition. Sleep Med Clin. 2018 Sep;13(3):443-56. doi: 10.1016/j.jsmc.2018.04.011.
Almey A, Milner TA, Brake WG. Estrogen receptors in the central nervous system and their implication for dopamine dependent cognition in females. Horm Behav. 2015 Aug;74:125-38. doi: 10.1016/j.yhbeh.2015.06.010.
Wharton W, Gleason CE, Olson SR, Carlsson CM, Asthana S. Neurobiological underpinnings of the estrogen mood relationship. Curr Psychiatry Rev. 2012 Aug 1;8(3):247-56. doi: 10.2174/157340012800792957.
Chhibber A, Woody SK, Karim Rumi MA, Soares MJ, Zhao L. Estrogen receptor β deficiency impairs BDNF 5 HT2A signaling in the hippocampus of female brain: a possible mechanism for menopausal depression. Psychoneuroendocrinology. 2017 Aug;82:107-16. doi: 10.1016/j.psyneuen.2017.05.016.
Hwang WJ, Lee TY, Kim NS, Kwon JS. The role of estrogen receptors and their signaling across psychiatric disorders. Int J Mol Sci. 2020 Dec 31;22(1):373. doi: 10.3390/ijms22010373.
Villa A, Vegeto E, Poletti A, Maggi A. Estrogens, neuroinflammation, and neurodegeneration. Endocr Rev. 2016 Aug;37(4):372-402. doi: 10.1210/er.2016-1007.
Wu CK, Tseng PT, Wu MK, Li DJ, Chen TY, Kuo FC, et al. Antidepressants during and after menopausal transition: a systematic review and meta analysis. Sci Rep. 2020 May 15;10(1):8026. doi: 10.1038/s41598-020-64910-8.
Swales DA, Lozza Fiacco S, Andersen EH, Cooper JA, Treadway MT, Xia K, et al. Hormone sensitivity predicts the beneficial effects of transdermal estradiol on reward seeking behaviors in perimenopausal women: a randomized controlled trial. Psychoneuroendocrinology. 2023 Oct;156:106339. doi: 10.1016/j.psyneuen.2023.106339.
Glynne S, Kamal A, McColl L, Newson L, Reisel D, Mu E, et al. Transdermal oestradiol and testosterone therapy for menopausal depression and mood symptoms: retrospective cohort study. Br J Psychiatry. 2025 Jun 16:1-10. doi: 10.1192/bjp.2025.101.
Chen H, Wu S, Chen H, Zeng G, Wu W, Chen X, et al. Efficacy and safety of hormone replacement combined with escitalopram in the treatment of chronic insomnia in perimenopausal women: a randomized controlled trial. CNS Neurosci Ther. 2025 Jun;31(6):e70470. doi: 10.1111/cns.70470.
Glynne S, Kamal A, Kamel AM, Reisel D, Newson L. Effect of transdermal testosterone therapy on mood and cognitive symptoms in peri and postmenopausal women: a pilot study. Arch Womens Ment Health. 2025 Jun;28(3):541-50. doi: 10.1007/s00737-024-01513-6.
Kulkarni J, Mu E, Li Q, Malicka M, Gavrilidis E, de Castella A, et al. Bazedoxifene plus conjugated estrogen to treat menopausal depression—A pilot study. J Pharmacol Exp Ther. 2025 Apr;392(4):103527. doi: 10.1016/j.jpet.2025.103527.
Tseng PT, Chiu HJ, Suen MW, Zeng BS, Wu MK, Tu YK, et al. Pharmacological interventions and hormonal therapies for depressive symptoms in peri and post menopausal women: a network meta analysis of randomized controlled trials. Psychiatry Res. 2023 Aug;326:115316. doi: 10.1016/j.psychres.2023.115316.
Borozan S, Kamrul Hasan ABM, Pappachan JM. Hormone replacement therapy for menopausal mood swings and sleep quality: the current evidence. World J Psychiatry. 2024 Oct 19;14(10):1605-10. doi: 10.5498/wjp.v14.i10.1605.
Grigolon RB, Ceolin G, Deng Y, Bambokian A, Koning E, Fabe J, et al. Effects of nutritional interventions on severity of depressive and anxiety symptoms of women in the menopausal transition and menopause: a systematic review, meta analysis, and meta regression. Menopause. 2023 Jan;30(1):95-107. doi: 10.1097/GME.0000000000002098.
Zhao FY, Zheng Z, Fu QQ, Conduit R, Xu H, Wang HR, et al. Acupuncture for comorbid depression and insomnia in perimenopause: a feasibility patient assessor blinded, randomized, and sham controlled clinical trial. Front Public Health. 2023 Feb 6;11:1120567. doi: 10.3389/fpubh.2023.1120567.
He S, Wang Z, Dong S, Diao Y, Qiao H, Lin X, Gao X. Effect of acupuncture on menopausal depressive disorder and serum hormone levels: a systematic review and meta analysis. Front Psychiatry. 2025 Jul 14;16:1591389. doi: 10.3389/fpsyt.2025.1591389.
Cho K, Kim M. Effects of aromatherapy on depression: A meta-analysis of randomized controlled trials. Gen Hosp Psychiatry. 2023 Sep-Oct;84:215-225. doi: 10.1016/j.genhosppsych.2023.08.003.
Ye M, Shou M, Zhang J, Hu B, Liu C, Bi C, et al. Efficacy of cognitive therapy and behavior therapy for menopausal symptoms: a systematic review and meta analysis. Psychol Med. 2022 Feb;52(3):433-45. doi: 10.1017/S0033291721005407.
Han B, Duan Y, Zhang P, Zeng L, Pi P, Chen J, et al. Effects of exercise on depression and anxiety in postmenopausal women: a pairwise and network meta analysis of randomized controlled trials. BMC Public Health. 2024 Jul 8;24(1):1816. doi: 10.1186/s12889-024-19348-2.
Xu H, Liu J, Li P, Liang Y. Effects of mind body exercise on perimenopausal and postmenopausal women: a systematic review and meta analysis. Menopause. 2024 May;31(5):457-67. doi: 10.1097/GME.0000000000002336.
Kim DS, Kim NY, Han DH, Kim HJ, Yu ES, Kim SM. Efficacy of cognitive behavioral therapy for menopausal symptoms and quality of life in Korean perimenopausal women: a pilot randomized controlled trial. Maturitas. 2024 Nov;189:108103. doi: 10.1016/j.maturitas.2024.108103.
Demirhan Kayacik A, İlcioglu K. Effects of melatonin intake on depression and anxiety in postmenopausal women: a systematic review and meta analysis of randomized controlled trials. Arch Womens Ment Health. 2024 Apr;27(2):265-73. doi: 10.1007/s00737-023-01395-0.
Sharifpour Z, Hasanpoor S, Mohammad Alizadeh Charandabi S, Mousavi Z, Shaseb E, Mirghafourvand M. The effect of ginseng on sexual function in postmenopausal women with major depression: a triple blind randomized controlled trial. J Pharm Health Care Sci. 2025 Jun 18;11(1):52. doi: 10.1186/s40780-025-00461-2.
Rattanatantikul T, Maiprasert M, Sugkraroek P, Bumrungpert A. Efficacy and safety of nutraceutical on menopausal symptoms in post menopausal women: a randomized, double blind, placebo controlled clinical trial. J Diet Suppl. 2022;19(2):168-83. doi: 10.1080/19390211.2020.1853648.
Luan H, Liu Q, Guo Y, Fan H, A S, Lin J. Effects of soy isoflavones on menopausal symptoms in perimenopausal women: a systematic review and meta analysis. PeerJ. 2025 Jul 23;13:e19715. doi: 10.7717/peerj.19715.
Li J, Li H, Yan P, Guo L, Li J, Han J, et al. Efficacy and safety of phytoestrogens in the treatment of perimenopausal and postmenopausal depressive disorders: a systematic review and meta analysis. Int J Clin Pract. 2021 Oct;75(10):e14360. doi: 10.1111/ijcp.14360.
Karalis S, Karalis T, Malakoudi F, Thanasas I, Kleisiari AS, Tzeli Z, et al. Role of phytoestrogen in menopausal women with depressive symptoms: a consecutive case series study. Cureus. 2023 Apr 6;15(4):e37222. doi: 10.7759/cureus.37222.
Mehrnoush V, Darsareh F, Roozbeh N, Ziraeie A. Efficacy of the complementary and alternative therapies for the management of psychological symptoms of menopause: a systematic review of randomized controlled trials. J Menopausal Med. 2021 Dec;27(3):115-31. doi: 10.6118/jmm.21022.
Stute P, Lozza Fiacco S. Strategies to cope with stress and anxiety during the menopausal transition. Maturitas. 2022 Dec;166:1-13. doi: 10.1016/j.maturitas.2022.07.015.
Littleton Kearney MT, Ostrowski NL, Cox DA, Rossberg MI, Hurn PD. Selective estrogen receptor modulators: tissue actions and potential for CNS protection. CNS Drug Rev. 2002 Fall;8(3):309-30. doi: 10.1111/j.1527-3458.2002.tb00230.x.
Tempfer CB, Hilal Z, Kern P, Juhasz Boess I, Rezniczek GA. Menopausal hormone therapy and risk of endometrial cancer: a systematic review. Cancers (Basel). 2020 Aug 6;12(8):2195. doi: 10.3390/cancers12082195.
Conde DM, Verdade RC, Valadares ALR, Mella LFB, Pedro AO, Costa Paiva L. Menopause and cognitive impairment: a narrative review of current knowledge. World J Psychiatry. 2021 Aug 19;11(8):412-28. doi: 10.5498/wjp.v11.i8.412.
Whooley MA, Grady D, Cauley JA. Postmenopausal estrogen therapy and depressive symptoms in older women. J Gen Intern Med. 2000 Aug;15(8):535-41. doi: 10.1046/j.1525-1497.2000.04029.x.
Azizi M, Khani S, Kamali M, Elyasi F. The efficacy and safety of SSRIs and SNRIs in the treatment of menopausal hot flashes: a systematic review of clinical trials. Iran J Med Sci. 2022 May;47(3):173-93. doi: 10.30476/ijms.2020.87687.1817.
Qi Q, Zhang X, Yao L, Chen Y, Weng H. Pueratin improves diminished ovarian reserve by inhibiting apoptosis. Exp Ther Med. 2021 Dec;22(6):1423. doi: 10.3892/etm.2021.10858.
Zhou L, Xiong JY, Chai YQ, Huang L, Tang ZY, Zhang XF, et al. Possible antidepressant mechanisms of omega 3 polyunsaturated fatty acids acting on the central nervous system. Front Psychiatry. 2022 Aug 31;13:933704. doi: 10.3389/fpsyt.2022.933704.
Eriksen EF. Hormone replacement therapy or SERMs in the long term treatment of osteoporosis. Minerva Ginecol. 2012 Jun;64(3):207-21. PMID: 22635016.
Cardona Gómez GP, Mendez P, DonCarlos LL, Azcoitia I, Garcia Segura LM. Interactions of estrogens and insulin like growth factor I in the brain: implications for neuroprotection. Brain Res Brain Res Rev. 2001 Nov;37(1 3):320 34. doi: 10.1016/S0165-0173(01)00137-0.
Kulkarni J, Gavrilidis E, Thomas N, Hudaib AR, Worsley R, Thew C, t al. Tibolone improves depression in women through the menopause transition: a double blind randomized controlled trial of adjunctive tibolone. J Affect Disord. 2018 Aug 15;236:88 92. doi: 10.1016/j.jad.2018.04.103.
Johnson A, Roberts L, Elkins G. Complementary and alternative medicine for menopause. J Evid Based Integr Med. 2019;24:2515690X19829380. doi: 10.1177/2515690X19829380.
Pickering G, Mazur A, Trousselard M, Bienkowski P, Yaltsewa N, Amessou M, et al. Magnesium status and stress: the vicious circle concept revisited. Nutrients. 2020 Nov 28;12(12):3672. doi: 10.3390/nu12123672.
Pal MM. Glutamate: the master neurotransmitter and its implications in chronic stress and mood disorders. Front Hum Neurosci. 2021 Oct 29;15:722323. doi: 10.3389/fnhum.2021.722323.
Jewett BE, Thapa B. Physiology, NMDA receptor. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; [Updated: 11-Dec-2022; Cited:10-Jan-2024]. Available from: https://www.ncbi.nlm.nih.gov/books/NBK519495/.
Paterni I, Granchi C, Katzenellenbogen JA, Minutolo F. Estrogen receptors alpha (ERα) and beta (ERβ): subtype selective ligands and clinical potential. Steroids. 2014 Nov;90:13 29. doi: 10.1016/j.steroids.2014.06.012.
Sirotkin AV, Harrath AH. Phytoestrogens and their effects. Eur J Pharmacol. 2014 Oct 15;741:230 6. doi: 10.1016/j.ejphar.2014.07.057.
Bu L, Lephart ED. Soy isoflavones modulate the expression of BAD and neuron specific beta III tubulin in male rat brain. Neurosci Lett. 2005 Sep 9;385(2):153 7. doi: 10.1016/j.neulet.2005.05.040.
Kotsopoulos D, Dalais FS, Liang YL, McGrath BP, Teede HJ. The effects of soy protein containing phytoestrogens on menopausal symptoms in postmenopausal women. Climacteric. 2000 Sep;3(3):161 7. doi: 10.1080/13697130008500108.
Gautam M, Tripathi A, Deshmukh D, Gaur M. Cognitive behavioral therapy for depression. Indian J Psychiatry. 2020 Jan;62(Suppl 2):S223 S229. doi: 10.4103/psychiatry.IndianJPsychiatry_772_19.
Villaverde Gutiérrez C, Torres Luque G, Ábalos Medina GM, Argente del Castillo MJ, Guisado IM, Guisado Barrilao R, et al. Influence of exercise on mood in postmenopausal women. J Clin Nurs. 2012 Apr;21(7 8):923 8. doi: 10.1111/j.1365-2702.2011.03972.x.
Blinov DV, Akarachkova ES, Ampilogova DM, Dzhobava EM, Tsibizova VI, Solopova AG, et al. Depression in postmenopause: interdisciplinary approach in management and perspectives for rehabilitation. Obst Gynecol Reprod. 2022 Jan;15(6):738 54. doi: 10.17749/2313-7347/ob.gyn.rep.2021.280.
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).